Evidence of a role for RANKL in the development of myeloma bone disease.

Abstract

Multiple myeloma is associated with the development of a devastating bone disease mediated by increased osteoclastic activity. The ligand for receptor activator of nuclear factor-kappaB (RANKL) plays a critical role in normal osteoclast biology and is abnormally regulated in myeloma. Targeting this system with recombinant decoy receptor, osteoprotegerin, or soluble forms of the receptor activator of nuclear factor-kappaB is able to prevent myeloma bone disease in pre-clinical models. Intriguingly, inhibiting osteoclast formation and bone resorption, and altering the bone marrow microenvironment, results in an indirect anti-myeloma effect.

• Authors: Evy De Leenheer, Gabrielle S Mueller, Karin Vanderkerken, Peter I Croucher
• Journal: Current opinion in pharmacology (Curr Opin Pharmacol) Vol. 4 Issue 4 Pg. 340-6 (Aug 2004) ISSN: 1471-4892 [Print] England
• PMID: 15251126 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Carrier Proteins
• Glycoproteins
• Membrane Glycoproteins
• Osteoprotegerin
• RANK Ligand
• Receptor Activator of Nuclear Factor-kappa B
• Receptors, Cytoplasmic and Nuclear
• Receptors, Tumor Necrosis Factor
• TNFRSF11A protein, human
• TNFRSF11B protein, human
• TNFSF11 protein, human

Topics

• Animals
• Bone Resorption (etiology)
• Carrier Proteins (physiology)
• Glycoproteins (physiology, therapeutic use)
• Humans
• Membrane Glycoproteins (physiology)
• Multiple Myeloma (complications, drug therapy)
• Osteoprotegerin
• RANK Ligand
• Receptor Activator of Nuclear Factor-kappa B
• Receptors, Cytoplasmic and Nuclear (physiology, therapeutic use)
• Receptors, Tumor Necrosis Factor